Celldex Therapeutics (CLDX) Shares Outstanding (Weighted Average) (2010 - 2026)

Celldex Therapeutics' Shares Outstanding (Weighted Average) history runs 17 years deep, the most recent figure standing at $66.6 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) changed 0.28% year-over-year to $66.6 million; the TTM figure through Mar 2026 stood at $66.6 million (changed 0.28% YoY), while the FY2025 annual figure was $66.4 million, up 3.15% from the prior year.
• Shares Outstanding (Weighted Average) was $66.6 million for Q1 2026 at Celldex Therapeutics, roughly flat from $66.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $66.6 million in Q1 2026 to a low of $46739.0 in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $18.4 million across 5 years, with a median of $62445.0 in 2024.
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Weighted Average) tumbled 99.89% in 2022, then surged 112660.1% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $46888.0 in 2022, then jumped by 103229.21% to $48.4 million in 2023, then jumped by 32.91% to $64.4 million in 2024, then advanced by 3.15% to $66.4 million in 2025, then gained by 0.22% to $66.6 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $66.6 million (Q1 2026), $66.4 million (Q4 2025), and $66399.0 (Q3 2025), per Business Quant data.